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Familial hypercholesterolaemia (FH) is a common, serious 
disease affecting all ethnic groups in South Africa. It can be 
diagnosed by clinical features and routine laboratory tests at 
primary health care level. Effective treatment prevents early 
and debilitating cardiovascular disease.
FH is an autosomal dominantly inherited disorder.1 The 
heterozygous phenotype is characterised by a personal or 
family history of premature ischaemic heart disease, tendon 
xanthomata and elevated plasma low-density lipoprotein 
(LDL) cholesterol levels (5 - 12 mmol/l). The homozygous 
phenotype displays tendon and cutaneous xanthomata, 
higher plasma LDL levels (>15 mmol/l), and often presents in 
childhood with physical signs or complications of the disease. 
Although the heterozygous phenotype can be due to at least 
3 genes, it most commonly results from mutations in the LDL 
receptor (LDLR). Mutations in apolipoprotein B, the ligand 
binding circulating LDL to the LDLR, can produce the same 
phenotype, as well as mutations in the proconvertase subtilin/
kexin type 9 (PCSK9) gene, which regulates LDLR turnover.
FH was first reported in SA in 1977.2 A higher-than-expected 
number of subjects with homozygous FH suggested a founder 
effect in Afrikaners.3 In this group, 3 mutations were identified 
in the LDLR.4 The prevalence of FH by these genotypes in a 
rural community was determined to be 1/83,5 compared with 
a worldwide prevalence estimate of 1/500. Several additional 
mutations have been described in South Africa6 in various 
population groups.
We describe here the experience with the first 1 000 patients 
presenting with the FH phenotype at the Groote Schuur 
Hospital Lipid Clinic. Clinical and biochemical data were 
analysed, along with genotyping for founder mutations after 
exclusion of binding defective apolipoprotein B100.
Methods
Informed consent for research into dyslipidaemia is obtained 
from all Lipid Clinic patients. Inclusion criteria for the FH 
phenotype included: an untreated cholesterol level of more 
than 7.5 mmol/l, attributable to an increase in LDL, together 
with a tendon xanthoma in the patient (or first-degree relative), 
and a personal or family history of premature ischaemic heart 
disease. Where the clinical diagnosis was suspected but data 
were incomplete, subjects with genetic confirmation were 
included in the analysis.
An overnight fast was required to determine plasma 
triglyceride (TG), total cholesterol (TC), high-density 
lipoprotein cholesterol (HDLC), and LDL cholesterol 
(LDLC) concentrations. Tests were done with automated 
analysers using commercial kits. Apolipoprotein AI (apoA-
I), apolipoprotein B (apoB) and lipoprotein (a) (Lp(a)) 
concentrations were also determined. Extraction of DNA7 
enabled the identification of the mutations reported in South 
Africa.8 Dysbetalipoproteinaemia was excluded by non-
denaturing gradient acrylamide gel electrophoresis9 and/or 
by genetic testing for mutations in apolipoprotein E. Agarose 
gel electrophoresis was performed on all new patients, using a 
Beckman Paragon system.
Statistical analyses were done with Graphpad Prism and 
Instat, taking p<0.05 as statistically significant.
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Familial hypercholesterolaemia (FH), an autosomal 
dominantly inherited disorder characterised by elevated 
plasma low-density lipoprotein (LDL) cholesterol levels, 
tendon xanthomata and premature ischaemic heart disease, is 
amenable to treatment with modern medication.
The clinical and biochemical details of 1 031 patients with 
FH were analysed. FH is the most common monogenic 
disorder of lipoprotein metabolism presenting to the Lipid 
Clinic at Groote Schuur Hospital, accounting for about 20% of 
consultations. The hospital classified 55% of the FH patients 
as white, 43% as coloured, 1.5% as Asian and 0.5% as black. In 
the FH cohort (whose mean age at presentation was 44 years), 
80% had tendon xanthomata, 36% had arcus cornealis, and 
14% had xanthelasma. Tendon xanthomata was present in 
almost 90% of patients by the age of 50 years. Arcus cornealis 
was present in about 45% by the age of 40 years, further 
increasing in frequency with age. Cardiovascular complications 
included ischaemic heart disease (43%), stroke (1.5%), transient 
ischaemic attacks (1.3%), and peripheral vascular disease 
(3.7%). The mean age of death was 55 (±13) years; 51 (±10) 
years in men and 61 (±12) years in women. In 46% of the 
cohort, a defective gene was identified by testing for locally 
prevalent mutations.
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Results and discussion
Demographics
Patients on the lipid clinic database totalled 4 494, with more 
women than men (53% v. 47%). FH constituted the most 
common monogenic dyslipidaemia (23%), and comprised 55% 
whites, 43% of persons of mixed ancestry (coloureds), and less 
than 2% Asians and 1% blacks. New patients over the same 
time period were distributed differently: whites 40%, coloureds 
56%, and Asians and blacks each 2% (Table I).
The prevalence of FH among whites presenting to the clinic 
is significantly higher than in the coloured group – 55% v. 43% 
(p<0.0001, chi-squared test). While this may simply reflect the 
high prevalence of FH due to the founder effect(s) in whites, 
it may also reflect a greater awareness of this disorder by their 
medical practitioners, or even a bias that FH is not present in 
other racial groups.
Estimating the prevalence of FH as being 1/100 for whites, 
1/200 in Asians and 1/500 in blacks and coloureds (the 
numbers of FH subjects calculated according to the 1991 
census) for the region within an hour’s drive from the Lipid 
Clinic, led to the figures of 5 700 whites, 100 Asians, 1 000 
blacks and 2 300 coloureds. The majority of these cases rely 
on public health care, requiring referral to the two tertiary 
hospitals for drug treatment. Assuming that an equal 
proportion attended each tertiary hospital, it is clear that 
many adults with FH were not referred, especially in the black 
population.
In the whole group, males presented younger than females: 
72% as opposed to 57% had presented by the age of 50 years 
(p<0.0001, Fisher’s exact test). White males (p=0.0002) and 
white females (p<0.0001) presented earlier to the clinic than 
those of mixed ancestry of either sex. The younger presentation 
is probably due to a greater awareness of FH in the white 
population and/or among medical practitioners. In contrast, 
blacks appeared to present latest, often only following a 
myocardial infarction, this occurring at an average age of 50 
years. These findings underscore the need to raise awareness 
of, and to screen for, FH in the population at large.
Physical signs
In the FH cohort, xanthelasma was uncommon (14%). Arcus 
cornealis was present in 36%, and 80% had tendon xanthomata. 
Xanthelasma was significantly commoner in females (p<0.0001, 
Fisher’s exact test). Arcus cornealis was commoner in males 
(p=0.0009, Fisher’s exact test) and in smokers (p<0.0001, 
Fisher’s exact test). The Achilles tendon was abnormal in the 
majority of cases (79%), but 1% had only extensor tendon 
xanthomata of the hand.
Physical signs of dyslipidaemia are uncommon before the 
age of 25 years. There is a marked increase in the prevalence 
of tendon xanthomata from 12% before the age of 25 years up 
to 75% by the age of 40 years, and about 90% by the age of 50 
years. In both sexes, tendon xanthomata are present in the third 
decade and well established by the age of 40 years. While the 
prevalence of tendon xanthomata in males remains static with 
age, it increases progressively in females, from 76% at the age 
of 40 to 91% by the age of 70 years (Fig. 1).
Arcus cornealis is present in about 25% of FH subjects by 
the age of 40 years and about 45% by the age of 50 years; by 
the age of 75 years more than 75% of the cohort was affected, 
Table I. Demographics of the clinic and 1 029 patients with FH
Race/sex  Whole clinic % of clinic Without FH With FH  % of FH cohort
Total number 4 494    3 469 (77%)  1 029 (23%)
Males  2 109 (47%)   1 626 (47%)  488 (47%)
Females  2 384 (53%)    1 843 (53%)  541 (53%)
    
White males 923 (21%)    641 (70%)  282 (30%) 
                 40       55
White females  848 (19%)    560 (66%)  288 (34%) 
          
Coloured males 1 060 (24%)    873 (82%)  187 (18%) 
                57        43
Coloured females 1 474 (33%)   1 224 (83%) 250 (17%)
Asian males 60 (1.3%)    47 (78%)  13 (22%)
                2       0.6
Asian females  26 (0.6%)    22 (85%)   4 (15%)
          
Black males 66 (1.5%)    63 (94%)   3 (6%) 
               2        0.5
Black females  36 (0.8%)    34 (95%)   2 (5%) 
}
}
}
}
}
}
}
}
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possibly due to senescence (arcus senilis). There was no 
difference in the prevalence of xanthelasma at presentation 
in males and females (p=0.3), but arcus occurred significantly 
earlier in males (p=0.0001), as did tendon xanthomata 
(p<0.0001, chi-squared test).
Referral letters accompanying patients almost invariably 
commented on xanthelasma, but seldom on arcus cornealis and 
practically never on tendon xanthomata. This implies that, with 
the exception of xanthelasma, clinical signs did not present 
a selection bias in our analysis of physical signs. An Achilles 
tendon xanthoma is a valuable physical sign for screening for 
individuals with a high risk of heart disease and to diagnose 
FH, especially after the age of 40 years.
The association of lipid profiles, including Lp(a), with 
physical signs was examined (Table II). Patients with 
xanthelasma had higher fasting plasma TG (p=0.04), TC 
(p=0.002) and LDLC (p=0.003) (chi-squared test) concentrations 
than those without xanthelasma. Patients with arcus cornealis 
had higher TC (p=0.0006) and LDLC (p<0.0001) (chi-squared 
test) concentrations than those without. In patients with tendon 
xanthomata, TG (p<0.0001), TC (p=0.006), and LDLC (p=0.015) 
and Lp(a) (p<0.0001) (chi-squared test) levels were higher than 
in those without tendon xanthomata. HDLC concentration 
was significantly lower (p<0.012) in subjects with tendon 
xanthomata. The pathogenesis of the physical signs is not well 
understood. Although chronic exposure to high concentrations 
of LDLC largely determines the development of physical signs, 
HDL and very low density lipoprotein (VLDL) metabolism 
may play an additional role in the pathogenesis of tendon 
xanthomata and xanthelasma, respectively.
Lipid profiles
In untreated fasting lipid profiles the TG concentrations 
increase with age in both genders (ANOVA, p<0.0001). There 
was no significant difference in the TC, HDLC or LDLC levels 
with increasing age, nor in the Lp(a) levels. In concordance 
with LDLC and HDLC, the apo B and apoA-I concentrations 
also did not change with age. According to the Fredrickson 
classification of agarose gel electrophoresis, 80% were type IIa 
and 20% were type IIb. This suggests that there may be slight 
increases in VLDL in FH, in response to other common genetic 
and environmental factors, including the metabolic syndrome 
(Table III).
Genotype results
All 3 genes causing the heterozygous FH phenotype relate to 
impaired clearance of LDL and are inherited in an autosomal 
dominant fashion. The most common cause of FH is the LDL 
receptor (LDLR) gene, with more than 840 different mutations 
on record.10
Mutations in apoB may result in a milder phenotype of FH, 
especially in children,11 but the adult phenotype is generally 
regarded as indistinguishable from that caused by LDLR 
mutations.12,13 The identification of 11 index cases with FDB 
accounted for 1.1% of the FH phenotypes and is too small for 
statistical comparison. Pro-protein convertase subtillin/kexin 
type 9 (PCSK9) encodes neural apoptosis regulated convertase 
1 (NARC1) and regulates the LDL receptor activity,14 but there 
is also evidence for over-production of lipoproteins in these 
contributes significantly to the familial hypercholersterolaemia phenotype in the
indigenous South African population of mixed ancestry. Clin Genet 1999; 55: 340-345.
Accepted 5 November 2007.
Fig. 1.
Cumul
ative incidence of physical signs in the whole familial hypercholesterolaemia cohort at age
of presentation to the clinic (Xma = tendon xanthoma; Arcus = arcus cornealis; Xsma =
xanthelasma).
0 25 50 75 100
0
25
50
75
100
Xsma
Arcus
Xma
Age in years
%
o
f
F
H
c
o
h
o
rt
Fig. 1. Cumulative incidence of physical signs in the whole familial 
hypercholesterolaemia cohort at age of presentation to the clinic (Xma 
= tendon xanthoma; Arcus = arcus cornealis; Xsma = xanthelasma).
Table II. Lipid and lipoprotein studies in patients with and without physical signs of hyperlipidaemia in the cohort of 1 029 
subjects with familial hypercholesterolaemia
Whole cohort  TG     TC              HDLC            LDLC           Lp(a)
With xsma  1.8  (0.8)       9.6  (2.0)        1.2 (0.4)         7.6 (2.0)        40 (44)
Without xsma     1.7  (1.0)        9.1  (1.7)        1.2 (0.4)         7.1 (1.7)        40 (43)
p-value         0.04              0.002             0.09               0.003              0.17
With arcus           1.7  (0.9)        9.4  (1.8)        1.14 (0.4)       7.5 (1.8)         42 (42)
Without arcus      1.7  (1.0)        9.0  (1.6)        1.19 (0.4)       7.0 (1.7)         39 (43)
p-value             0.51              0.001              0.046            0.0001      0.21
With xma       1.8  (0.9)      9.2  (1.8)        1.15 (0.4)      7.3  (1.8)         48 (42)
Without xma          1.5  (1.0)      8.9  (1.5)        1.2   (0.4)      7.0  (1.5)         41 (37)
p-value                    0.0001    0.006  0.012            0.015             0.0001
Units are mmol/l except for Lp(a) in mg/dl. Mean (SD). 
Xsma = xanthelasma; xma = tendon xanthoma; arcus = arcus cornealis.
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Table III. Plasma lipid, lipoprotein and apoprotein concentrations at age of presentation of patients with familial 
hypercholesterolaemia
Age groups     
(yrs)  12 - 19          20 - 29 30 - 39          40 - 49 50 - 59          60 - 69 >70
Males
N=488  30          61                  130          131                  91           38           7
TG   1.0 (0.5)          1.4 (0.8)  1.9 (1.1)           2.0 (1.0)  1.9 (0.8)          2.1 (0.9)  1.7 (1.0)
TC   8.2 (1.1)          9.8 (1.1)  9.3 (1.9)           9.1 (1.6)  8.6 (1.4)          8.3 (1.2)  9.5 (1.5)
HDLC   1.1 (0.3)          1.0 (0.4)  1.0 (0.3)           1.1 (0.4)  1.0 (0.3)           1.1 (0.4) 1.2 (0.4)
LDLC  6.7 (1.2)          8.1 (2.0)  7.5 (1.7)           7.4 (1.7)  6.7 (1.5)           6.4 (1.4) 7.5 (1.8)
ApoA-I  92 (21)           102 (25)  100 (24)           107 (26) 108 (27)           114 (29)  112 (21) 
ApoB  154 (51)           164 (40)  153 (38)           152 (41) 155 (36)           148 (35)  157 (59)
Lp(a)   31 (26)           35 (26)  29 (24)           40 (29) 36 (26)          31 (26) 32 (31)
Females
N=541  26          57  105          119           131          81   22
TG  1.1 (0.7)           1.1 (0.5)  1.3 (0.6)           1.6 (0.9)  2.0 (1.2)           2.0 (0.9) 1.9 (0.9)
TC   9.3 (1.5)           9.1 (1.8)  9.6 (1.6)          9.1 (1.7)  9.3 (1.7)          9.2 (1.8) 9.6 (1.6)
HDLC  1.2 (0.3)           1.3 (0.6)  1.3 (0.4)          1.2 (0.4)  1.3 (0.5)          1.3 (0.4) 1.4 (0.5)
LDLC  7.5 (1.4)           7.4 (1.6)  7.7 (1.6)          7.1 (1.8)  7.1 (1.8)          7.0 (1.8) 7.4 (1.6)
ApoA-I 109 (23)           109 (30)  118 (38)          116 (27)  126 (37)           124 (34) 142 (44)
ApoB  173 (54)           149 (30)  155 (43)          152 (41)  159 (38)           159 (46) 176 (45)
Lp(a)  32 (25)           24 (21)  36 (26)          30 (25)  39 (29)           37 (29)  20 (19)
Units are mmol/l for TG, TC, HDLC and LDLC. ApoA1, apoB and Lp(a) values are given in mg/dl. Mean (SD). TG and Lp(a) were log-transformed for calculations.
Table IV. Genotyping for locally prevalent (founder) mutations in the cohort of 1 029 patients with familial 
hypercholesterolaemia
Mutation   White  Mixed  Asian   Black  Total   %
Unknown   217 (38%)  332 (76%)  1 (6%)     5   555   54
Known    353 (62%)  105 (24%)  16 (94%)     0   474   46
Afr 3      D154N 26 (23)  6 (2)  0     0   32  3.1
Lith      Del197 21 (14)   8 (2)  0     0   29  2.8
Afr 1      D206E  190 (156)  32 (20)  0     0   222  21.4
Afr 2      V408M 98 (61)   17 (95)   0     0   115  11.2
Gujerat      P664L   0  2 (2)  9 (1)      0  11  1.1
CT 2      DelEx7.8 0  12 (8)  0      0  12  1.2
Percentages of known genotypes are calculated from the whole group. 
( ) = No. of kindreds; % = percentage within each racial group.
patients.15 This disorder was not sought, but is expected to 
contribute a very small proportion of our patients.
Genetic analysis is summarised in Table IV. All patients 
were screened for locally prevalent (9) LDLR mutations. The 
genotyping in whites reflects the founder effects of D154N, 
D206E and V408M in Afrikaners and del197 in Jews, but 
these mutations are also present in subjects of mixed ancestry. 
Founder effects have occurred for E207K and P664L in the 
Asian (Indian) communities, while none of the tests identified 
LDLR mutations in blacks.
With this limited diagnostic strategy, approximately 47% 
of the FH phenotype could be proven by genetic studies. The 
founder effects permitted 94% identification in Indians and 
62% in whites. In accordance with a previous publication,16 
76% of white Afrikaners could be identified by their 3 founder 
genes. In contrast, only 24% of FH could be identified in the 
mixed ancestry population where the Afrikaner mutations 
predominated. This agrees with a previous analysis of this 
cohort in the clinic.17 The 2.5 kb deletion of exons 7 and 8 
(Cape Town 2) mutation appears to be exclusive to the mixed 
ancestry group.
Complications
Cardiovascular complications are displayed in Table V. Cardiac 
complications, including death, occurred more frequently in 
males than in females, but still affected more than a third of 
females. Other vascular complications were uncommon and 
occurred equally in both sexes.
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Only 43% of the FH cohort had ischaemic heart disease 
(IHD), at presentation and during follow-up, with males 
predominating (52% v. 34%, p=0.0005, Fisher’s exact test). 
Of those developing IHD, 68% were smokers, with a higher 
percentage in males (78% v. 55%, p<0.0001, Fisher’s exact test). 
Hypertension was present in 24% with IHD, with more female 
hypertensives (33% v.16%, p<0.0001, Fisher’s exact test).
Stroke was remarkably uncommon in the FH cohort 
(1.6%) and had a strong association with smoking (94%) and 
hypertension (63%), but there was no association with body 
mass index, waist/hip ratio, HDLC, LDLC and Lp(a).
Peripheral vascular disease (PVD) was uncommon (<4%). 
The prevalence of smoking in patients with PVD was high 
(79%), especially in males (95% v. 63%). About a quarter of 
the FH cohort with PVD was diabetic. Diabetes was present 
in about 5% of the entire FH cohort and occurred similarly in 
males and females.
The average age of death in the FH cohort followed at the 
clinic was 54.9 (±13) years, with that of men being 51.4 (±10) 
and women 60.5 (±12) years. More males died during follow-
up, and their age at death was 10 years younger than that for 
females, although this was not statistically significant (p=0.09, 
Fisher’s exact test).
We compared cardiovascular disease in the first 122 
genotyped FH patients in 1994 with the current analysis. There 
was no significant difference in the average age of onset of 
angina pectoris (46 ± 11 years) or myocardial infarction (45 ± 
11 years). This may reflect a failure to diagnose FH and thus 
a failure to undertake preventive action. In contrast, there 
was a significant delay in the average age of death, from 48 
years to 55 years (p=0.012, unpaired t-test). The improvement 
in survival is probably due to treatment with statins. LDLC 
levels were generally lowered by about 30% to 40% with 
20 mg of simvastatin given at night. In addition it is likely 
that aggressive lifestyle management, especially lowering of 
cholesterol and saturated fat intake and cessation of smoking, 
played significant roles.
Conclusions
FH is a common heritable disorder which can be diagnosed 
clinically at primary health care level. A strong predisposition 
to premature coronary artery disease (CAD) can be 
modulated by lifestyle and drug treatment. Although FH is 
most commonly encountered in Afrikaners, it occurs in all 
communities and is under-diagnosed. Simple screening of TC 
by a finger-prick test and a good family history and physical 
examination would identify most FH individuals. A raised 
TC (>7.5 mmol/l) or LDLC (>5 mmol/l) level in the presence 
of normal TG suggests the diagnosis and is confirmed by 
presence of a tendon xanthoma.
Genetic confirmation of the diagnosis of FH is not always 
successful. As a result of founder effects, 76% of the Afrikaners 
were confirmed to have LDLR mutations, whereas only 25% 
in the coloured group could be confirmed genetically, using 
a limited strategy for genotyping. In the Jewish patients, 65% 
had FH Lithuania, and 2 mutations accounted for 94% of FH in 
the Indian patients.
A diet low in cholesterol and saturated fat lowered the TC 
by 1.5 mmol/l (data not shown), and should be started during 
childhood. Statin doses should be titrated to achieve a target 
LDLC level of 2.5 mmol/l in secondary prevention and in 
lower-risk subjects, to 3 mmol/l. Individuals vary considerably 
in response, and monotherapy may not be sufficient. 
Experienced practitioners should undertake combination 
treatment. The age to commence drug therapy is not clearly 
established and may be influenced by cardiovascular risk 
factors such as hypertension, family history of very premature 
IHD, and the concentrations of LDLC, HDLC and Lp(a). In 
general, men should be treated from their early twenties and 
women later, especially if they plan to have children early in 
their reproductive years.
Lipid clinics can efficiently diagnose and equitably treat FH 
while providing valuable clinical, biochemical and genotypic 
information. This approach is valuable for determining factors  
 
Table V. Cardiovascular complications in cohort of 1 029 patient with familial hypercholesterolaemia
FH cohort  IHD Angina  MI  Stroke  TIA  PVD  Death
All patients  
N = 1029   438 375 237   16 10 38 107
% of cohort  43  36  23  1.5 1.3 3.7 10
Males
N = 488   251  205 161 10 4  19 76 
% of males  52 42  33  2 0.6 3.9  16 
Females
N = 541   186 170  76 6 6  19  31
% of females  34  31 14 1 1 3.5  6
Males v. females
p-value   <0.0001 0.0005  <0.0001 NSS  NSS NSS <0.0001
IHD = ischaemic heart disease; MI = myocardial infarction; TIA = transient ischaemic attack; N = number; NSS = not statistically significant.
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that modulate the natural history as well as the other genes 
responsible for the FH phenotype of this severe disorder. 
Owing to the high prevalence of FH, patients should continue 
treatment at primary and secondary health care services. 
Family members should be investigated.
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EDITORIAL
UCT Surgery Update 
Saturday 15 to Sunday 16 March 2008 
Groote Schuur Hospital, Cape Town, South Africa 
We invite you to attend the University of Cape Town Department of Surgery Update 
Conference 'Practical Solutions for Common Surgical Problems'. The programme is 
aimed at General Surgeons and Surgical Registrars as well as General 
Practitioners and Medical Officers with a surgical aspect to their practice.
The topics have been selected specifically to address common surgical problems 
and dilemmas faced in everyday surgical practice. The emphasis will be on 
relevant and up to date management of a broad range of general surgical issues. 
Presentations will be practical with evidence based advice.
Professor Derek Alderson, an upper gastrointestinal surgeon, from Birmingham, 
UK will be the guest speaker. 
The presentations will run from 8am Saturday 15 March to 4pm Sunday 16 March 
2008 to minimise disruption to private practice and other clinical duties.  
The conference will be CPD accredited. 
For programme, registration information and accommodation options,
please contact: 
UCT Conference Management Centre 
Barnard Fuller Building, UCT Faculty of Health Sciences, 
Anzio Road Observatory, 7925 Cape Town South Africa 
Tel: +27 21 406 6167 Fax: +27 21 448 6263 
Email: deidre.raubenheimer@uct.ac.za
Website: www.cmc.uct.ac.za
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